| Tittel: | Drug repurposing and the COVID-19 pandemic | | Ansvar: | James Nurton | | Forfatter: | Nurton, James  | | Materialtype: | Artikkel - elektronisk | | Signatur: | WIPO Magazine | | Utgitt: | Geneva : WIPO, 2020 | | Omfang: | S. 22-29 | | ISBN/ISSN: | 1564-7854 | | Serie: | WIPO Magazine ; 2/2020 | | Emneord: | Korona - COVID-19 / Pandemi | | Innhold: | The COVID-19 pandemic has prompted worldwide interest in the repurposing of drugs such as remdesivir and dexamethasone. Repurposing can be crucial for delivering
new treatments to patients, but also raises a number of IP-related questions.
In May 2020, the US Food and Drug Administration (USFDA) authorized emergency use of the anti-viral drug remdesivir for the treatment of COVID-19 after research
suggested that patients who received it recovered four days faster than those receiving a placebo. The drug has not yet been approved, and further clinical trials are
taking place to assess its effectiveness against COVID-19, including in combination with the anti-inflammatory drug baricitinib (sold under the brand name Olumiant). In June 2020, in a breakthrough in treating seriously-ill COVID patients on ventilators or oxygen, the low-cost anti-inflammatory steroid dexamethasone, which has been shown to significantly improve survival rates, became the “standard of care” in the UK. | | Del av verk: | WIPO Magazine 2/2020 |
|
|